SCHEMBL3667828

SCHEMBL3667828

C1=CC2C=Cc3ccccc3CC2C=C1

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.35
PARP1 P09874 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15372654 0.73
SCHEMBL11149573 0.73 IDO1 (0.32) IDO1
SCHEMBL22361781 0.73 IDO1 (0.48) IDO1
SCHEMBL28139148 0.72 PARP1 (0.36) IDO1PARP1
SCHEMBL24292921 0.70 GAA (0.35)
SCHEMBL18026599 0.68 PARP1 (0.36) IDO1PARP1
SCHEMBL15233622 0.68 PARP1 (0.36) IDO1PARP1
SCHEMBL4824305 0.68 IDO1 (0.40) IDO1PARP1
SCHEMBL2524855 0.68 PARP1 (0.36) IDO1PARP1
SCHEMBL8161816 0.68 CYP19A1 (0.37) IDO1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0587670-A4 PCP RECEPTOR LIGANDS AND THE USE THEREOF. OREGON STATE (US) 1995-02-01 EP claimed
EP-0587670-A1 PCP RECEPTOR LIGANDS AND THE USE THEREOF STATE OF OREGON, acting through OREGON STATE BOARD OF HIGHER EDUCATION, acting for OREGON HEALTH SC. UNIV. AND UNIV. OF OREGON (US) 1994-03-23 EP claimed
EP-3328856-A2 ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS Vyome Biosciences Pvt. Ltd. (IN) 2018-06-06 EP disclosed
WO-2017044575-A1 CONSTRAINED BENZHYDRYL SULFONAMIDES AS ANTICANCER AND NEUROPROTECTIVE AGENTS ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2017-03-16 WO disclosed
WO-2017017631-A2 ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS VYOME BIOSCIENCES PVT. LTD. (IN) 2017-02-02 WO disclosed
EP-2681209-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISORDERS Aquilus Pharmaceuticals, Inc (US) 2014-01-08 EP disclosed
EP-2648707-A1 HYDROXYLATED TRICYCLIC COMPOUNDS Nektar Therapeutics (US) 2013-10-16 EP disclosed
WO-2012118498-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISORDERS AQUILUS PHARMACEUTICALS, INC. (US) 2012-09-07 WO disclosed
WO-2012079017-A1 HYDROXYLATED TRICYCLIC COMPOUNDS NEKTAR THERAPEUTICS (US) 2012-06-14 WO disclosed
EP-2139887-A2 METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY Alantos Pharmaceuticals Holding, Inc. (US) 2010-01-06 EP disclosed
EP-2125816-A2 METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY Alantos Pharmaceuticals Holding, Inc. (US) 2009-12-02 EP disclosed
WO-2003087059-A2 (E)-OXIME ETHER DERIVATIVE OF 5,6-DIHYDRO-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDIN-11-ONE SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2003-10-23 WO disclosed
US-6242198-B1 ADMINISTERING GUANIDINE COMPOUND CAMBRIDGE NEUROSCIENCE, INC. 2001-06-05 US disclosed
EP-0918460-A1 METHODS OF TREATMENT OF EYE TRAUMA AND DISORDERS CAMBRIDGE NEUROSCIENCE, INC. (US) 1999-06-02 EP disclosed
WO-1999002145-A1 COMBINATION DRUG THERAPIES COMPRISING AMINOGLYCOSIDE ANTIBIOTICS AND N,N'-DISUBSTITUTED GUANIDINES CAMBRIDGE NEUROSCIENCE, INC. (US) 1999-01-21 WO disclosed
WO-1998004131-A1 METHODS OF TREATMENT OF EYE TRAUMA AND DISORDERS CAMBRIDGE NEUROSCIENCE, INC. (US) 1998-02-05 WO disclosed
EP-0587670-A4 PCP RECEPTOR LIGANDS AND THE USE THEREOF. OREGON STATE (US) 1995-02-01 EP disclosed
EP-0587670-A1 PCP RECEPTOR LIGANDS AND THE USE THEREOF STATE OF OREGON, acting through OREGON STATE BOARD OF HIGHER EDUCATION, acting for OREGON HEALTH SC. UNIV. AND UNIV. OF OREGON (US) 1994-03-23 EP disclosed
WO-1993015100-A1 NOVEL ADENOSINE DERIVATIVES, THEIR PREPARATION METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LABORATOIRES UPSA (FR) 1993-08-05 WO disclosed
EP-0208855-A1 Process for preparing piperidylidene dihydrodibenzo(a,d)cycloheptenes and aza derivatives thereof, compounds obtained by such process and the use of such compounds for preparing useful pharmaceutical compositions SCHERING CORPORATION (US) 1987-01-21 EP disclosed